Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines [Yahoo! Finance]
Veracyte, Inc. (VCYT)
Last veracyte, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.veracyte.com/investor-relations
Company Research
Source: Yahoo! Finance
that its market-leading Decipher Prostate Genomic Classifier is the only gene expression test to be included in version 1 of the 2025 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) as part of the updated "Advanced Tools" table located in the Principles of Risk Stratification and Biomarkers section (PROS-H) . "The Decipher Prostate test's performance and clinical utility have been demonstrated in many dozens of peer-reviewed, published studies, including analyses of samples from multiple prospective, Phase 3 clinical trials, making it the most validated test of its kind for prostate cancer," said Phil Febbo, M.D., Veracyte's chief scientific officer and chief medical officer. "We believe the Decipher Prostate test's unique status in the NCCN guidelines stems from the evidence generated through our commitment to research and our numerous collaborations with leading prostate cancer researchers around the world." The Decipher Prostate test is a whole-transcriptome-
Show less
Read more
Impact Snapshot
Event Time:
VCYT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCYT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCYT alerts
High impacting Veracyte, Inc. news events
Weekly update
A roundup of the hottest topics
VCYT
News
- Is Your Portfolio Missing These 5 High-Growth Healthcare Stocks? [Yahoo! Finance]Yahoo! Finance
- 3 Medical Instruments Industry Stocks to Buy on the GenAI Wave [Yahoo! Finance]Yahoo! Finance
- Those who invested in Veracyte (NASDAQ:VCYT) a year ago are up 68% [Yahoo! Finance]Yahoo! Finance
- Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer GuidelinesBusiness Wire
- Veracyte, Inc. (NASDAQ: VCYT) had its "neutral" rating re-affirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $37.00 price target on the stock, down previously from $38.00.MarketBeat
VCYT
Earnings
- 11/6/24 - Beat
VCYT
Sec Filings
- 12/17/24 - Form 4
- 12/13/24 - Form 144
- 12/6/24 - Form 4
- VCYT's page on the SEC website